Skp2是F-box protein的一種，它能藉由調控細胞週期的抑制者─ p27Kip1，來促進細胞週期由G1期前進至S 期。p42/p44 MAP Kinase的活化也是促使細胞週期前進所需要的分子。p27Kip1會抑制細胞週期G0期及G1期的cyclin-cdk複合物的活性，所以是細胞週期的負向調控者。本實驗係利用反轉錄聚合酵素連鎖反應，西方墨點法和免疫組織染色法，來評估三者在子宮頸癌的形成過程中所扮演的角色。在反轉錄聚合酵素連鎖反應及西方墨點法，Skp2在子宮頸癌的組織表現量都很多。在Fisher’s exact test顯示，Skp2、p27Kip1和p42/p44 MAP Kinase 三者與疾病的進展上都有顯著的相關性(P < 0.0001, P = 0.006, P = 0.003)。再者，Skp2與p42/p44 MAP Kinase也有顯著的正向相關(P = 0.0003)。

The F-box protein Skp2 (S-phase kinase associated protein 2) positively regulates the G1-S transition by controlling the cell cycle inhibitor p27Kip1. The p42/p44 mitogen-activated protein (MAP) kinase activation is also necessary for the cell cycle progression. p27Kip1 acts as a negative regulator of the cell cycle by inhibiting the activity of cyclin/cdk complexes during G0 and G1. RT-PCR, Western blotting and immunohistochemical staining were used to assay their relationship with cervical lesion development. In RT-PCR and western blotting, Skp2 mRNA and protein were expressed mostly in carcinoma tissues. At Fisher’s exact test showed that Skp2, p27Kip1 and p42/p44 MAP Kinase are strongly associated with disease progession respectively (P < 0.0001, P < 0.0001, P = 0.0043). We also found a postive correlation between the expression of Skp2 and p42/p44 MAP Kinase (P = 0.0097).

目錄
中文摘要------------------------------------------------p.1
英文摘要------------------------------------------------p.2
緒 論------------------------------------------------p.3
子宮頸癌---------------------------------------------p.3
p27Kip1------------------------------------------------p.4
Skp2 (S-phase kinase-associated protein 2 )----------p.6
Mitogen (maturation)-activated protein (MAP) kinase--p.9
實驗目的-----------------------------------------------p.12
實驗材料與方法-----------------------------------------p.13
反轉錄聚合酵素連鎖反應------------------------------p.13
西方墨點法------------------------------------------p.15
免疫組織染色法--------------------------------------p.18
統計分析--------------------------------------------p.19
實驗結果與討論-----------------------------------------p.20
參考文獻-----------------------------------------------p.27
附圖---------------------------------------------------p.36

Bloom,J. and Pagano, M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Seminars in Cancer Biology 13:41-47(2003)

Catzavelos, C., Bhattacharva, N., Ung, Y.C., Wilson, J.A., Roncari, L. and Sanhu, C. Decreased levels of the cell-cycle inhibitor p27 inhibitor protein: prognostic implications in primary breast cancer. Nat. Med. 3:227-230(1997)

Carrano, A.C., Eytan, E., Hershko, A. and Pagano. M. Skp2 is required　for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol. 1:193-199(1999)

Cenciarelli, C., Chiaur, D.S., Guardavaccaro, D., Parks, W., Vidal, M. and Pagano, M. Identification of a family of human F-box proteins. Curr. Biol. 9:1177-1179(1999)

Cheung, T.H., Lo, K.W., Yu, M.M., Yim, S.F., Poon, C.S., Chung, T.K. and Wong, Y.F. Aberrant expression of p21 (WAF1/CIP1) and p27 (KIP1) in cervical carcinoma. Cancer Let. 172:93-98(2001)

Cho, N.H., Kim, Y.T. and Kim, J.W. Alteration of cell cycle in cervical tumor associated with human papillomavirus- cyclin-dependent kinase inhibitors. J. Yons. Med. 43:722-728(2002)

Delmas, C., Manenti, S., Boudjelal, A., Peyssonnaux, C., Eychenes, A. and Darbon, J. The p42/p44 mitogen-activated protein kinase activation triggers p27 Kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells. J. Biol. Chem. 276:34958-34965(2001)

DeMay, R. M. The Art & Science of Cytopathology – Exfoliative Cytology. 90-92(1996)

Demetrick, D.J., Zangh, H. and Beach, D. Chromosomal mapping of the genes for the human CDK2/cyclin A-associated proteins p19 (SKP1A and SKP1B) and p45 (SKP2) Cytogenet Cell Genet. 73:104-107(1996)

Dowen, S.E., Neutze, D.M., Pett, M.R., Cottage, A., Stern, P., Coleman, N. and Stanley, M.A. Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes. Oncogene 22:2531-2540(2003)

Dowen, S.E., Scott, A., Mukher, J.G. and Stanley M.A. Overexpression of Skp2 in carcinoma of the cervix does not correlate inversely with p27 expression. Int. J. Cancer 105:326-330(2003)

Draetta, G.F. Mammalain G1 cyclins. Curr. Opin. Cell Biol. 6: 842-846(1994)

Eggstein, S., Franke, M., Kutschka, I., Manthey, G., Specht, B.U., Ruf, G. and Farthmann, E.H. Expression and activity of mitogen activated protein kinases in human colorectal carcinoma. Gut. 44:834-838(1999)

Erlanson, M., Portin, C., Linderholm, B., Lindh, J., Roos, G. and Landberg, G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas: prognostic implications. Blood 92:770-777(1998)

Esposito, V., Baldi, A., Luca, A.D., Groger, A.M., Loda, M., Giordano, G.G., Caputi, M., Baldi, F., Pagano, M. and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor: p27 in non-small cell lung cancer. Cancer Res. 57:3381-3385(1997)

Fero, M.L., Tasch, M., Porter, P., Carow, E., Firpo, E., Polyak, K., Tsai, L.H., Brouby, V., Perlmutter, R.M., Kaushansky, K. and Roberts, J.M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85:733-744(1996)

Gstaiger, M., Jordan, R., Lim, M., Catzavelos, C., Mestan, J., Slingerland, J. and Krek, W. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. USA. 98:5043-5048(2001)

Goff, B.A., Sallin, J., Garcia, R., VanBlaricom, A., Paley, Pamela. J. and Muntz, H. G. Evaluation of p27 in preinvasive and invasive malignancies of the cervix. Gynecol. Oncol. 88:40-44(2003)

Hara, T., Kamura, T., Nakayamas, K., Oshikawa, K., Hatakeyama, S. and Nakayama, K. Degradation of p27Kip at the G0-G1 transition mediated by a Skp2-independent ubiquitination pathway. J. Biol. Chem. 276:48937-48943(2001)

Hengst, L. and Reed, S.I. Translational control of p27Kip1 accumulation during the cell cycle. Science 271:1861-1864(1996)

Hershko, D., Bornstein, G., Ben-Izhak, O., Carrano, A., Pagano, M., Krausz, M.M. and Hershko, A. Inverse relation between levels of p27 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 91:1745-1751(2001)

Huang, L.W., Chao, S.L., Hwang, J.L. and Chou, Y.Y. Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecologic Oncology 85:524-528(2002)
Hwang, C.F., Su, C.Y., Huang, S.C., Huang, C.C., Fang, F.M., Lui, C.C., Chang, H.W. and Cho, C.L. Low expression levels of p27 correlate with loco-regional recurrence in nasopharyngeal carcinoma. Cancer Let. 189:231-236(2003)

Ito, Y., Matsuura, N., Sakon, M., Miyoshi, E., Noda, K., Takeda, T., Umeshita, K., Nagano, H., Nakamori, S., Dono, K., Tsujimoto, M., Nakahara, M., Nakao, K., Taniguchi, N. and Monden, M. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 30:90-99(1999)

Jeffrey C.H. Donovan, Milic, A. and Slingerland, J.M. Constitutive MEK/MAPK activation leads to p27Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J. Biol. Chem. 276:40888-40895(2001)

Jordan, RCK., Bradley, G. and Slingerland, J. Reduced levels of the cell-cycle inhibitor p27 in　epithelial dysplasia and oral cavity. Am. J. Pathol. 52: 585-590(1998)

Khokhlatchev, A.V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E. and Cobb, M.H. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 93:605-615(1998)

Kim,Y. T., Choi, E.K., Cho, N.H., Ko, J.H., Yang, W.I., Kim, J.W. and Lee, S.H. Expression of cyclin E and p27 in cervical carcinoma. Cancer Lett. 153:41-50(2000)

Kortylewski, M., Heinrich, P.C., Kauffmann, M.E., Bohm, M., Mackiewicz, A. and Behrmann, I. Mitogen-activated protein kinase control p27/Kip1 expression and growth of human melanoma cells. J. Biochem. 357:297-303(2001)
Kudo, Y., Kitajima, S., Sato, S., Miyauchi, M., Ogawa, I. and Takata, T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinoma. Cancer Res. 6:7044-7047(2001)

Kularni, S., Rader, J.S., Zhang, F., Liapis, H., Koki, A.T., Masferrer, K.S. and Dannenberg A.J. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7:429-434(2001)

Kurman, R.J. and Solomon, D. The Bethesda System for Reporting Cervical / Vaginal Cytologic Diagnosis. 44-56(1994)

Latres, E., Chiarl, R., Schulman, B., Pellicer, A., Inghirami, G. and Pagano, M. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl. Acad. Sci. USA 98:2515-2520(2001)

Li, Li., Wysk, M., Gonzalez, F.A., and Davis, R.J. Oncogene 9:647-649(1994)

Masuda, T., Inoue, H., Sonoda, H., Mine, S., Yoshikawa, Y., Nakayama, K., Nakayama, K. and Mori, M. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: Modulation of malignant phenotype by Skp2 overexpression possibly via p27 proteolysis. Cancer Re. 62:3819-3825(2002)

Morisaki, H., Fujimoto, A., Ando, A., Nagata, Y., Ikeda, K. and Nakanishi, M. Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (cdk) inhibitor by cyclin E/cdk2. Biochem. Biophys. Res. Commun. 240:386-390(1997)

Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D.Y. and Nakayama, K. Mice lacking p27 (Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pipuitary tumors. Cell 85:702-720(1996)

Nakayama K.I., Hatakeyama, S. and Nakayama, K. Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27. Biochem. Biophys. Res. Commun. 282:853-860(2001)

Nakayama, K., Nagahama, H., Minamishima, Y.A., Matsumoto, M., Nakamichi, I., Kitagawa, K., Shirane, M., Tsunematsu, R., Tsukiyama, T., Ishida, N., Kitagawa, K. and Hatakeyama, S. Targeted disruption of Skp2 results in accumulation of cyclin E and p27 (Kip1),polyploidy and centrosome overduplication. EMBO J. 19:2069-2081(2000)

Nitti, D., Belluco, C., Mammano, E., Marchet, A., Ambrosi, A., Mencarelli, R., Segato, P. and Lise, M. Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J. Surgi. Oncol. 81:167-176(2002)

Pagano, M., Tam, S.W., Theodoras, A.M., Beer-Romero, P., Del Sal, G., Chau. V., Yew, P.R., Draetta, G.F. and Rolfe, M. Role of ubiquitin-proteaome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685(1995)

Palmqvist, R., Stenling, R., Oberg, A. and Landberg, G. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J. Pathol. 188:18-23(1999)

Philipp-Staheli, J., Payne, S, R. and Kemp, C.J. p27 Kip1: Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Experi. Cell Res. 264:148-168(2001)

Pietenpol, J.A., Bohlander, S. K., Sato, Y., Papadopoulos, N., Liu, B., Friedman, C., Trask, B.J., Roberts, J.M., Kinzler, K.W. and Rowley, J.D. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 55:1206-1210(1995)

Pu, Q.Q. and Streuli, C. H. Integrin control of cell cycle: a new role for ubiquitin ligase. BioEssays. 24:17-21(2002)

Reszka, A.A., Seger, R., Diltz, C.D., Krebs, E.G. and Fischer, E.H. Association of mitogen-activated protein kinase with the microtubule cytoskeleton. Proc. Natl. Acad. Sci. USA 92:8881-8885(1995)

Rossomando, A.J., Sanghera, J.S., Matsden, L.A., Weber, M.J., Pelech, S. L.and Sturgill, T.W. Biochemical characterization of a family of serine/threonine protein kinase regulated by tyrosine and serine/threonine phosphorylations. J. Biol. Chem. 266:20270-20275(1991)

Sherr, C.J. and Roberts, J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149-1163(1995)

Skomedal, H., Kristensen, G.B., Lie, A.K. and Holm, R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol. Oncol. 73:223-228(1999)

Slingerland, J. and Pagano, M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. cell. Phys. 183:10-17(2000)
Shiozawa, T., Shiohara, S., Kanai, M., Konishi, I., Fujii, S. and Nikaido, T., Expression of the cell cycle regulator p27Kip1 in normal squamous epithelium, cervical intraepithelial neoplasia, and invasive squamous cell carcinoma of the uterine cervix. Cancer 92:3005-3011(2001)

Thomas, G. Map kinase by any other name smells just as sweet. Cell 68:3-6(1992)

Troncone, G., Vetrani, A., Rosa, G., Gerbasio, D. and Palombini, L. Cyclin dependent kinase inhibitor p27 Kip1 expression in normal and neoplastic cervical epithelium. J. Clin. Pathol. 52:880-887(1999)

Tsihlias, J., Kapusra, L. R., Deboer, G., Morava-Protzner, I., Zbier-anowski, I. and Bhattacharya, N. Loss of cyclin-dependent kinase inhibitor p27 (Kip1) is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58:542-548(1998)

Tsvetkov, L.M., Yeh, K., Lee, S., Sun, H., and Zang, H. p27 ubiquitination and degradation is regulated by the SCF complex through phosphorylated Thr187 in p27. Curr. Biol. 9:661-664(1999)

Vlach, J., Hennecke, S. and Amati, B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 16:5334-5344(1997)

Yokoi, S., Yasui, K., Iizasa, T., Takahashi, T., Fujisawa, T. and Inazawa, J. Down-regulation of SKP2 induces apoptosis in lung-cancer cells. Cancer Sci. 94:344-349(2003)

Zerfass-Thome, K., Zwerschke, W., Mannhardt, B., Tindle, R., Botz, J.W.and Jansen-Durr, P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13:2323-2330(1996)

Zhang, H., Kobayashi, R., Galaktionov, K., and Beach, D. p19 (Skp1) and p45 (Skp2) are essential elements of the cyclin A-CDK2 S phase kinase. Cell 82:915-925(1995)